The drug has been launched in the Indian market under an exclusive licensing agreement, the companies said in a joint statement.
The product has been developed by Helsinn and Glenmark has exclusive marketing rights for it in India and Nepal, it added.
"Akynzeo is a single-dose oral capsule for each chemotherapy cycle that covers both the acute and delayed phase of chemotherapy-induced nausea and vomiting (CINV)," Glenmark President India Formulations, Middle East and Africa Sujesh Vasudevan said.
The product is already being marketed in the EU, the US and several other leading markets of the world, the statement said.
Shares of Glenmark were trading at Rs 582.50 per scrip on BSE, up 0.09 per cent from the previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)